Please use this identifier to cite or link to this item:
https://accedacris.ulpgc.es/handle/10553/35366
Title: | Retrospective evaluation of COX-2 expression, histological and clinical factors as prognostic indicators in dogs with renal cell carcinomas undergoing nephrectomy |
Authors: | Carvalho, S. Stoll, A. L. Priestnall, S. L. Suárez-Bonnet, A. Rassnick, K. Lynch, S. Schoepper, I. Romanelli, G. Buracco, P. Atherton, M. De Merlo, E. M. Lara-Garcia, A. |
UNESCO Clasification: | 3109 Ciencias veterinarias |
Keywords: | Canine renal cell carcinoma Chemotherapy COX-2 expression Histologictype Metastasis, et al |
Issue Date: | 2017 |
Publisher: | 1476-5810 |
Journal: | Veterinary and comparative oncology |
Abstract: | Limited veterinary literature is available regarding prognostic markers for canine renal cell carcinoma (CRCC). We retrospectively evaluated COX-2 expression, histological and clinical features associated with prognosis of CRCC. Sixty-four cases post-nephrectomy were included, 54 had histopathological assessment and 30 had COX-2 immunostaining performed. Eight dogs (13\%) had metastatic disease at initial diagnosis. Twenty-seven dogs (42\%) received adjuvant therapy after nephrectomy. On univariate analysis, COX-2 expression, mitotic index (MI), histologic type, vascular invasion, neoplastic invasiveness and metastasis at diagnosis were significantly associated with overall median survival time (MST). COX-2 score (COX-2 score > 3 MST 420 days versus 1176 days if cox-2 score < 3; p = 0.011) and MI (MI > 30 MST 120 days versus 540 days for mi < 30; p = 0.003) were the only variables associated with CRCC outcome on multivariate analysis. The addition of MI and COX-2 immunostaining to standard histopathological evaluation would help predicting outcome in CRCC patients. |
URI: | https://accedacris.ulpgc.es/handle/10553/35366 |
ISSN: | 1476-5810 |
DOI: | 10.1111/vco.12264 |
Source: | Veterinary and Comparative Oncology [ISSN 1476-5810], v. 15 (4), p. 1280-1294 |
Appears in Collections: | Articles |
Items in accedaCRIS are protected by copyright, with all rights reserved, unless otherwise indicated.